Represented VolitionRx (NYSE MKT: VNRX) in connection with an underwritten public offering consisting of 3,500,000 shares of its common stock at a price of $2.40 per share, for gross proceeds of $8.4 million. The sole book-running manager was Oppenheimer & Co. Inc. with National Securities Corporation acting as co-manager. Volition intends to use the net proceeds of the offering for continued product development, clinical studies, product commercialization, working capital, and other general corporate purposes.
Volition is a life sciences company focused on developing diagnostic tests for cancer. The tests are based on the science of Nucleosomics®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid -- an indication that disease is present.
The deal team representing VolitionRx was led by Marc Alcser and included Jason Lee and Matthew Brodsky.